|
Subject
Characteristics.
|
IL-12
Dose
(ng/kg)
|
Administration
Route
|
Patient
|
Sex
|
Age
|
Prior
Therapya
|
Visceral
Metastases
|
Completed
Protocol
|
|
0
|
i.v.
|
1
|
M
|
59
|
None
|
Y
|
Y
|
|
2
|
M
|
54
|
IT
|
Y
|
Y
|
|
3
|
F
|
42
|
RT
|
Y
|
N
|
|
s.c.
|
4
|
M
|
59
|
RT,
CT, BCT, IT
|
Y
|
N
|
|
5
|
F
|
59
|
CT,
IT
|
Y
|
Y
|
|
6
|
F
|
63
|
None
|
N
|
Y
|
|
7
|
F
|
27
|
IT
|
Y
|
N
|
|
10
|
i.v.
|
8
|
M
|
58
|
CT,
IT
|
Y
|
N
|
|
9
|
M
|
53
|
IT
|
Y
|
N
|
|
10
|
M
|
69
|
CT,
IT
|
Y
|
N
|
|
s.c.
|
11
|
M
|
52
|
BCT
|
Y
|
N
|
|
12
|
M
|
63
|
RT, CT, IT
|
Y
|
N
|
|
13
|
M
|
40
|
CT, IT
|
Y
|
Y
|
|
14
|
F
|
55
|
RT, BCT, IT
|
Y
|
Y
|
|
15
|
F
|
56
|
CT
|
Y
|
Y
|
|
16
|
F
|
50
|
BCT
|
Y
|
Y
|
|
30
|
i.v.
|
17
|
F
|
62
|
CT, IT
|
N
|
Y
|
|
18
|
F
|
45
|
IT
|
N
|
Y
|
|
19
|
M
|
40
|
None
|
Y
|
Y
|
|
s.c.
|
20
|
M
|
38
|
BCT, IT
|
Y
|
Y
|
|
21
|
F
|
76
|
RT
|
Y
|
Y
|
|
22
|
M
|
30
|
IT
|
N
|
Y
|
|
100
|
i.v.
|
23
|
M
|
66
|
CT, IT
|
Y
|
Y
|
|
24
|
M
|
35
|
CT
|
Y
|
N
|
|
25
|
M
|
59
|
None
|
Y
|
N
|
|
s.c.
|
26
|
F
|
41
|
IT
|
N
|
N
|
|
27
|
M
|
61
|
RT, CT
|
N
|
N
|
|
28
|
M
|
78
|
None
|
Y
|
N
|
aAbbreviations:
RT, radiotherapy; CT, chemotherapy; BCT, biochemotherapy; IT,
immunotherapy.
|